# L-Serine Supplementation in Hereditary Sensory Neuropathy Type 1

> **NCT01733407** · PHASE1,PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 18 (actual)

## Conditions studied

- Hereditary Sensory and Autonomic Neuropathy Type I

## Interventions

- **DRUG:** L-serine
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01733407
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2016-05
- **Final completion:** 2017-07
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2018-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01733407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01733407, "L-Serine Supplementation in Hereditary Sensory Neuropathy Type 1". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01733407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*